Pure Global AI
NCT06398925Completed

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

A Phase I, First-in-human, Randomised, Double-blind, Placebo-controlled, Single Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study to Investigate the Effects of OCT461201 in Healthy Volunteers
Oxford Cannabinoid Technologies Holdings PLCPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Healthy
Drug/Device/Intervention
OCT461201 50 mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Oxford Cannabinoid Technologies Holdings PLC
Location
Merthyr Tydfil, United Kingdom
Timeline & enrollment
Phase
Phase 1
Start date
Jul 26, 2023
End date
Sep 25, 2023
Enrollment
32 participants
Primary outcome

Number of Participants with Treatment Emergent Adverse Events during the study assessed as mild, moderate or severe

Summary

A study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of
 OCT461201. The study included a screening period, a single dose of study treatment or placebo
 and a follow up period.

ICD-10 classifications
ObesitySeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personLifestyle-related conditionMalnutrition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06398925
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06398925 through Pure Global AI's free database. This Phase 1 trial is sponsored by Oxford Cannabinoid Technologies Holdings PLC and is currently Completed. The study focuses on Healthy. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.